---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-347984"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2026-08-13T12:31:59+00:00"
generated_at: "2026-08-13T12:35:09.638038+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q2 net loss narrows to $30.2M; first patient dosed in lupus nephritis registrational trial

## Summary
- Net loss $30.2M ($0.25/share) vs $34.1M ($0.29/share) in Q2 2025; revenue $2.1M from Ono collaboration.
- Cash $153.8M at June 30, down $21M in quarter; runway expected into 2028.
- First patient dosed in RECLAIM-LN Phase 2 registrational trial for lupus nephritis with FT819; outpatient same-day discharge.
- FDA cleared IND for FT839 dual CD19/CD38 CAR T; Phase 1/2 basket trial in autoimmune disease planned.
- Preliminary SSc data: all 4 patients achieved rCRISS≥25 and mRSS improvement; no CRS/ICANS/GvHD.

## SEC filing metadata
- accession: 0001193125-26-347984
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2026-08-13T12:31:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312526347984/0001193125-26-347984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312526347984/fate-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-347984
- JSON: https://secwatch.observer/filing/0001193125-26-347984.json
- Plain text: https://secwatch.observer/filing/0001193125-26-347984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.